BACKGROUND: Therapy with fumaric acid esters (FAE) has been shown to be safe and effective in patients with severe psoriasis in several clinical studies with limited follow-up periods. In view of the chronic character of psoriasis, long-term safety aspects are of major importance in determining the suitability of a drug during prolonged periods of treatment. OBJECTIVES: To investigate adverse events of therapy with systemic FAE with follow-up periods of up to 14 years, in order to determine safety aspects of their long-term use in patients with severe psoriasis. METHODS: Current and/or past therapeutic use of FAE was reviewed in 66 patients with severe psoriasis. RESULTS: Forty-one of 66 patients had received FAE for at least 1 year, and 12 of these 41 patients had received FAE for between 10 and 14 years. Adverse events were reported in 73% of the patients. These were usually mild and mainly consisting of flushing (55%), diarrhoea (42%), nausea (14%), tiredness (14%) and stomach complaints (12%). A relative lymphocytopenia was observed in 76% of patients during therapy with FAE, resulting in a permanent discontinuation of therapy with FAE in four patients. A transient eosinophilia and moderate liver enzyme elevations were observed in 14% and 25% of patients, respectively. CONCLUSIONS: The present study indicates that FAE can be considered as a safe long-term treatment in patients with severe psoriasis.
BACKGROUND: Therapy with fumaric acid esters (FAE) has been shown to be safe and effective in patients with severe psoriasis in several clinical studies with limited follow-up periods. In view of the chronic character of psoriasis, long-term safety aspects are of major importance in determining the suitability of a drug during prolonged periods of treatment. OBJECTIVES: To investigate adverse events of therapy with systemic FAE with follow-up periods of up to 14 years, in order to determine safety aspects of their long-term use in patients with severe psoriasis. METHODS: Current and/or past therapeutic use of FAE was reviewed in 66 patients with severe psoriasis. RESULTS: Forty-one of 66 patients had received FAE for at least 1 year, and 12 of these 41 patients had received FAE for between 10 and 14 years. Adverse events were reported in 73% of the patients. These were usually mild and mainly consisting of flushing (55%), diarrhoea (42%), nausea (14%), tiredness (14%) and stomach complaints (12%). A relative lymphocytopenia was observed in 76% of patients during therapy with FAE, resulting in a permanent discontinuation of therapy with FAE in four patients. A transient eosinophilia and moderate liver enzyme elevations were observed in 14% and 25% of patients, respectively. CONCLUSIONS: The present study indicates that FAE can be considered as a safe long-term treatment in patients with severe psoriasis.
Authors: Nicolle H R Litjens; Jacobus Burggraaf; Elisabeth van Strijen; Co van Gulpen; Herman Mattie; Rik C Schoemaker; Jaap T van Dissel; H Bing Thio; Peter H Nibbering Journal: Br J Clin Pharmacol Date: 2004-10 Impact factor: 4.335
Authors: Robbert-Jan Gieselbach; Annemarie H Muller-Hansma; Martijn T Wijburg; Marjolein S de Bruin-Weller; Bob W van Oosten; Dennis J Nieuwkamp; Frank E Coenjaerts; Mike P Wattjes; Jean-Luc Murk Journal: J Neurol Date: 2017-05-23 Impact factor: 4.849
Authors: Ji Sun van Bezooijen; Deepak M W Balak; Martijn B A van Doorn; Caspar W N Looman; Marco W J Schreurs; Birgit C P Koch; Teun van Gelder; Errol P Prens Journal: Dermatology Date: 2016-09-01 Impact factor: 5.366
Authors: Irida Kastrati; Stacey E P Joosten; Svetlana E Semina; Luis H Alejo; Svitlana D Brovkovych; Joshua D Stender; Hugo M Horlings; Marleen Kok; Elaine T Alarid; Geoffrey L Greene; Sabine C Linn; Wilbert Zwart; Jonna Frasor Journal: Mol Cancer Res Date: 2020-04-03 Impact factor: 5.852